. | . | . | . | . | Gene expression (%) . | . | . | . | |||
---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | . | . | . | Reduced . | . | . | |||
Gene . | Experimental groups . | Dose/embryo . | Stage . | n* . | Unchanged . | Weakly . | . | Strongly . | |||
sox2 | Control MO | 8 ng | 10.5 | 30† | 90 | 7 | |||||
sox2 | FrdMO | 8 ng | 10.5 | 31 | 29 | 71 | |||||
sox2 | DprMO | 4 ng | 10.5 | 34 | 44 | 56 | |||||
sox2 | Control MO | 8 ng | 13 | 25 | 92 | 8 | 0 | ||||
sox2 | FrdMO | 8 ng | 13 | 31 | 13 | 32 | 55 | ||||
sox2 | DprMO | 4 ng | 13 | 29 | 38 | 24 | 38 | ||||
sox2 | Control MO | 8 ng | 19 | 14 | 100 | 0 | 0 | ||||
sox2 | FrdMO | 8 ng | 19 | 18 | 44 | 17 | 39 | ||||
sox2 | DprMO | 4 ng | 19 | 17 | 35 | 18 | 47 | ||||
nrp1 | Control MO | 8 ng | 20-21 | 175 | 95 | 5 | 0 | ||||
nrp1 | FrdMO | 8 ng | 20-21 | 265 | 6 | 37 | 57 | ||||
nrp1 | DprMO | 4 ng | 20-21 | 28 | 32 | 25 | 43 | ||||
nrp1 | FrdMO+Frodo | 8 ng+0.5 ng | 20-21 | 113 | 44 | 41 | 15 | ||||
nrp1 | FrdMO+Frodo | 8 ng+1 ng | 20-21 | 100 | 39 | 48 | 13 | ||||
myoD | Control MO | 8 ng | 14 | 25 | 92 | 8 | 0 | ||||
myoD | FrdMO | 8 ng | 14 | 37 | 78 | 14 | 8 | ||||
myoD | DprMO | 4 ng | 14 | 34 | 79 | 6 | 15 |
. | . | . | . | . | Gene expression (%) . | . | . | . | |||
---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | . | . | . | Reduced . | . | . | |||
Gene . | Experimental groups . | Dose/embryo . | Stage . | n* . | Unchanged . | Weakly . | . | Strongly . | |||
sox2 | Control MO | 8 ng | 10.5 | 30† | 90 | 7 | |||||
sox2 | FrdMO | 8 ng | 10.5 | 31 | 29 | 71 | |||||
sox2 | DprMO | 4 ng | 10.5 | 34 | 44 | 56 | |||||
sox2 | Control MO | 8 ng | 13 | 25 | 92 | 8 | 0 | ||||
sox2 | FrdMO | 8 ng | 13 | 31 | 13 | 32 | 55 | ||||
sox2 | DprMO | 4 ng | 13 | 29 | 38 | 24 | 38 | ||||
sox2 | Control MO | 8 ng | 19 | 14 | 100 | 0 | 0 | ||||
sox2 | FrdMO | 8 ng | 19 | 18 | 44 | 17 | 39 | ||||
sox2 | DprMO | 4 ng | 19 | 17 | 35 | 18 | 47 | ||||
nrp1 | Control MO | 8 ng | 20-21 | 175 | 95 | 5 | 0 | ||||
nrp1 | FrdMO | 8 ng | 20-21 | 265 | 6 | 37 | 57 | ||||
nrp1 | DprMO | 4 ng | 20-21 | 28 | 32 | 25 | 43 | ||||
nrp1 | FrdMO+Frodo | 8 ng+0.5 ng | 20-21 | 113 | 44 | 41 | 15 | ||||
nrp1 | FrdMO+Frodo | 8 ng+1 ng | 20-21 | 100 | 39 | 48 | 13 | ||||
myoD | Control MO | 8 ng | 14 | 25 | 92 | 8 | 0 | ||||
myoD | FrdMO | 8 ng | 14 | 37 | 78 | 14 | 8 | ||||
myoD | DprMO | 4 ng | 14 | 34 | 79 | 6 | 15 |
MOs and RNAs were injected into a single right animal-dorsal blastomere of 8- to 16-cell stage embryos. Whole-mount in situ hybridization was carried out with the pan-neural markers sox2 and nrp1, and the muscle marker myoD. The data obtained from two (myoD) or four(sox2 and nrp1) separate experiments are shown.
Number of scored embryos
3% of embryos injected with control MO showed expanded expression of nrp1